Nuvation Bio to present subgroup analyses from TRUST-I, TRUST-II taletrectinib studies in ROS1+ NSCLC at WCLC 2026

Reuters2026/08/04 12:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Nuvation Bio flagged new subgroup analyses from its pivotal Phase 2 TRUST-I and TRUST-II studies of IBTROZI (taletrectinib) in advanced ROS1-positive NSCLC.
The results have not been presented yet; they are scheduled for WCLC on Sept. 15, 2026, and ESMO on Oct. 26, 2026.
The analyses are intended to show durable benefit with a consistent safety profile across key patient subgroups, including previously treated patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608040800PR_NEWS_USPR_____NY18227) on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Nuvation Bio to present subgroup analyses from TRUST-I, TRUST-II taletrectinib studies in ROS1+ NSCLC at WCLC 2026

You may also like

Crypto prices